A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors

Trial Profile

A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer; Gastrointestinal cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 05 Jun 2018 Results (n=24) assessing safety, PK and preliminary efficacy in mCRC patients presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 13 Apr 2018 According to a Taiho Oncology media release, data from this trial is being presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR).
    • 05 Oct 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top